Skip to content

Clinical Pulmonary Embolism

Clinical Characteristics and Outcome Registry in Patients Admitted With Acute Pulmonary Embolism

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05469724
Enrollment
100
Registered
2022-07-22
Start date
2022-07-31
Completion date
2023-12-31
Last updated
2022-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pulmonary Embolism

Brief summary

To evaluate the clinical characteristics, risk factors, management and outcome of patients admitted e acute pulmonary embolism in chest diseases department and Respiratory Icu in Assiut University hospital

Detailed description

Pulmonary embolism (PE) occurs when there is a disruption to the flow of blood in the pulmonary artery or its branches by a thrombus that originated somewhere else. In deep vein thrombosis (DVT), a thrombus develops within the deep veins, most commonly in the lower extremities. PE usually occurs when a part of this thrombus breaks off and enters the pulmonary circulation. Very rarely, PE can occur from the embolization of other materials into the pulmonary circulation such as air, fat, or tumor cells.Risk factors can be classified as genetic and acquired. Genetic risk factors include thrombophilia such as factor V Leiden mutation, prothrombin gene mutation, protein C deficiency, protein S deficiency, hyperhomocysteinemia, among others. Acquired risk factors include immobilization for prolonged periods (bed rest greater than three days, anyone traveling greater than 4 hours, whether by air, car, bus, or train), recent orthopedic surgery, malignancy, indwelling venous catheter, obesity, pregnancy, cigarette smoking, oral contraceptive pill use Other predisposing factors for VTE include: Fracture of lower limb Hospitalization for heart failure or atrial fibrillation/flutter within the previous three months Hip or knee replacement Major trauma History of previous venous thromboembolism Central venous lines Chemotherapy Congestive heart failure or respiratory failure Hormone replacement therapy Oral contraceptive therapy Postpartum period Infection (specifically pneumonia, urinary tract infection, and HIV) Cancer (highest risk in metastatic disease) Thrombophilia Bed rest greater than three days Obesity Pregnancy Cancer carries a high risk for thrombus formation and hence, PE. Pancreatic cancer, hematological malignancies, lung cancer, gastric cancer, and brain cancer carry the highest risk for VTThe most common symptoms of PE include the following: dyspnea, pleuritic chest pain, cough, hemoptysis, presyncope, or syncope. Dyspnea may be acute and severe in central PE, whereas it is often mild and transient in small peripheral PE. In patients with preexisting heart failure or pulmonary disease, worsening dyspnea may be the only symptom. Chest pain is a frequent symptom and is usually caused by pleural irritation due to distal emboli causing pulmonary infarction.

Interventions

OTHERRole of ct pulmonary angiography in diagnosis of pulmonary embolism

Role of ct pulmonary angiography in diagnosis of acute pulmonary embolism as filling defect in pulmonary artery

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients above 18 years old and less than 75 year old

Exclusion criteria

* patients with chronic thromboembolism \_patient less than 18 years old

Design outcomes

Primary

MeasureTime frameDescription
European society of cardiology risk score and its measurement units1 yearClassification of patients admitted with acute pulmonary embolism into high risk ,low risk, intermediate high and intermediate low risk

Secondary

MeasureTime frameDescription
Pulmonary embolism severity index risk score and its units of measurement1 yearClassification of patients according to rik score of pulmonary embolism severity index

Contacts

Primary ContactPeter samir roshdy Poles, Master
peposamir781@gmail.com01097150423
Backup ContactSafaa mokhtar wafy Wafy
safaa_wafy@hotmail.com+20 122 414 2884

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026